Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998-2002

British Journal of Clinical Pharmacology

Volumn 63, Issue 1, 2007, Pages 85-91

  Balakrishnan, Komathi ^a   Tordoff, June ^a   Norris, Pauline ^a   Reith, David ^b,c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c DUNEDIN HOSPITAL   (New Zealand)

Author keywords

Formulations; Medicines; Off label; Paediatric; Unlicensed

Indexed keywords

BCG VACCINE; CISAPRIDE; HYALURONIC ACID; METHYLENE BLUE; PRIMIDONE; TUBERCULIN; YELLOW FEVER VACCINE;

ARTICLE; CHILD; CHILD HEALTH CARE; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG INDUSTRY; DRUG MARKETING; DRUG MONITORING; HUMAN; LICENSING; PRIORITY JOURNAL; UNITED KINGDOM;

CHILD; CHILD, PRESCHOOL; DRUG APPROVAL; DRUG THERAPY; GREAT BRITAIN; HUMANS; INFANT; LEGISLATION, DRUG; PEDIATRICS; PHARMACEUTICAL PREPARATIONS;

EID: 33845425396     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02729.x     Document Type: Article

References (29)

1. Turner S, Longworth A, Nunn AJ, Choonara I. Unlicensed and off label drug use in paediatric wards: prospective study. BMJ 1998; 316: 343-5.
2. Turner S, Gill A, Nunn T, Hewitt B, Choonara I. Use of 'off-label' and unlicensed drugs in paediatric intensive care unit. Lancet 1996; 347: 549-50.
3. Conroy S, McIntyre J, Choonara I. Unlicensed and off label drug use in neonates. Arch Dis Child Fetal Neonatal Ed 1999; 80: F142-4.
4. Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, Knoeppel C, Seyberth H, Pandolfini C, Raffaelli MP, Rocchi F, Bonati M, Jong G, de Hoog M, van den Anker J. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 2000; 320: 79-82.
5. Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 1999; 88: 965-8.
6. Nahata MC. Pediatric drug formulations: challenges and potential solutions. Ann Pharmacother 1999; 33: 247-9.
7. Brion F, Nunn AJ, Rieutord A. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals. Acta Paediatr 2003; 92: 486-90.
8. Tuleu C, Marques J, Yeung V, Wong I. Extemporaneous manipulation of drugs in a paediatric hospital pharmacy: an audit. Int J Pharm Pract 2003; 11: R78.
9. Standing JF, Tuleu C. Paediatric formulations - getting to the heart of the problem. Int J Pharm 2005; 300: 56-66.
10. Schirm E, Tobi H, de Vries TW, Choonara I, De Jong-van den Berg LT. Lack of appropriate formulations of medicines for children in the community. Acta Paediatr 2003; 92: 1486-9.
11. Ceci A, Felisi M, Catapano MPB, Cipollina L, Ravera S, Bagnulo S, Reggio S, Rondini G. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products. Eur J Clin Pharmacol 2002; 58: 495-500.
12. 't Jong GW, Stricker BH, Choonara I, van den Anker JN. Lack of effect of the European guidance on clinical investigation of medicines in children. Acta Paediatr 2002; 91: 1233-8.
13. The Compendium Team. Medicines Compendium 2002. London: Datapharm Communications Limited 2002.
14. The Compendium Team. Electronic Medicines Compendium 2002. CD-ROM. London: Datapharm Communications Limited 2002.
15. Walker G, ed. ABPI Compendium of Data Sheets and Summaries of Product Characteristics 1998. London: Datapharm Publications Limited 1998.
16. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Clinical Investigation of Medicinal Products in the Pediatric Population. 2000.
17. Chui J, Tordoff J, Kennedy J, Reith D. Trends in accessibility to medicines for children in New Zealand: 1998-2002. Br J Clin Pharmacol 2004; 57: 322-7.
18. Chui J, Tordoff J, Reith D. Changes in availability of paediatric medicines in Australia between 1998 and 2002. Br J Clin Pharmacol 2005; 59: 736-42.
19. Impicciatore P, Choonara I. Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use. Br J Clin Pharmacol 1999; 48: 15-18.
20. Tan E, Cranswick NE, Rayner CR, Chapman CB. Dosing information for paediatric patients: are they really 'therapeutic orphans'? Med J Aust 2003; 179: 195-8.
21. FDA. Best Pharmaceuticals for Children Act. Available at http://www.fda.gov/opacom/laws/pharmkids/contents.html 2002 (last accessed: 21 January 2004).
22. US Food and Drug Administration Centre for Drug Evaluation and Research. Food and Drug Administration Modernisation Act of 1997 - Section III. Pediatric Studies of Drugs. Available at http://www.fda.gov/cder/guidance/105-115.htm 2004 (last accessed: 5 March 2004).
23. Grieve J, Tordoff J, Reith D, Norris P. Effect of the Pediatric Exclusivity Provision on children's access to medicines. Br J Clin Pharmacol 2005; 59: 730-5.
24. Medicines and Healthcare products Regulatory Agency. MHRA/Department of Health Strategy on Medicines for Children. Available at http://medicines.mhra. gov.uk/ourwork/licensingmeds/children/children.htm 2005 (last accessed: 8 July 2005).
25. Wong I, Sweis D, Cope J, Florence A. Paediatric medicines research in the UK: how to move forward? Drug Saf 2003; 26: 529-37.
26. European Medicines Agency. European Paediatric Initiative. 2004. Available at http://www.emea.eu.int/pdfs/human/peg/1796704en.pdf (last accessed: 14 February 2006).
27. British Medical Association and Royal Pharmaceutical Society of Great Britain. BNF for Children. Available at http://www.bnf.org/bnf/extra/current/ noframes/450055.htm 2005 (last accessed: 2 June 2005).
28. Royal College of Paediatrics and Child Health. Medicines for Children. London: Royal College of Paediatrics and Child Health 1999.
29. Nahata MC, Morosco RS, Brady MT. Extemporaneous sildenafil citrate oral suspensions for the treatment of pulmonary hypertension in children. Am J Health Syst Pharm 2006; 63: 254-7.